Wanders R J, van Roermund C W, de Vries C T, van den Bosch H, Schrakamp G, Tager J M, Schram A W, Schutgens R B
Clin Chim Acta. 1986 Aug 30;159(1):1-10. doi: 10.1016/0009-8981(86)90160-9.
The presence of a beta-oxidation system in peroxisomes has been well documented. Rather than a duplicate of the mitochondrial beta-oxidation system, peroxisomes seem specially equipped to initiate the oxidation of very-long-chain fatty acids. Thus, the accumulation of very-long-chain fatty acids in tissues and body fluids from patients with a limited (X-linked adrenoleukodystrophy) or generalized (cerebro-hepato-renal (Zellweger) syndrome, infantile Refsum disease, neonatal adrenoleukodystrophy) peroxisomal dysfunction probably results from an impairment in the peroxisomal beta-oxidation system. In order to study this, we have developed an original assay which allows measurement of the overall peroxisomal beta-oxidation activity in human liver homogenates. Compared to controls, a strong deficiency of this activity was detected in liver from Zellweger patients using palmitoyl-CoA as a substrate.
过氧化物酶体中存在β-氧化系统已有充分的文献记载。过氧化物酶体似乎并非线粒体β-氧化系统的复制品,而是特别配备用于启动极长链脂肪酸的氧化。因此,患有局限性(X连锁肾上腺脑白质营养不良)或全身性(脑肝肾(泽尔韦格)综合征、婴儿型雷夫叙姆病、新生儿肾上腺脑白质营养不良)过氧化物酶体功能障碍的患者,其组织和体液中极长链脂肪酸的积累可能是由于过氧化物酶体β-氧化系统受损所致。为了对此进行研究,我们开发了一种原创性检测方法,可用于测量人肝匀浆中过氧化物酶体的整体β-氧化活性。与对照组相比,使用棕榈酰辅酶A作为底物时,在泽尔韦格患者的肝脏中检测到该活性严重缺乏。